Ra Pharmaceuticals Inc (NASDAQ:RARX) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 1,700,188 shares, an increase of 52.2% from the February 28th total of 1,117,092 shares. Currently, 10.1% of the company’s stock are short sold. Based on an average daily volume of 353,290 shares, the days-to-cover ratio is currently 4.8 days.
NASDAQ:RARX opened at $5.31 on Friday. Ra Pharmaceuticals has a one year low of $5.03 and a one year high of $27.84. The stock has a market capitalization of $171.44, a P/E ratio of -2.20 and a beta of 2.05.
Ra Pharmaceuticals (NASDAQ:RARX) last released its quarterly earnings results on Wednesday, March 14th. The company reported ($0.67) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.70) by $0.03. analysts forecast that Ra Pharmaceuticals will post -2.16 EPS for the current year.
In related news, major shareholder Enterprise Associates 13 L. New acquired 2,000,000 shares of Ra Pharmaceuticals stock in a transaction on Friday, February 16th. The shares were bought at an average price of $6.00 per share, for a total transaction of $12,000,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Ra Capital Healthcare Fund Lp acquired 2,500,000 shares of Ra Pharmaceuticals stock in a transaction on Wednesday, February 14th. The shares were bought at an average price of $6.00 per share, for a total transaction of $15,000,000.00. The disclosure for this purchase can be found here. Insiders own 14.50% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its stake in shares of Ra Pharmaceuticals by 47.9% in the fourth quarter. BlackRock Inc. now owns 952,580 shares of the company’s stock worth $8,097,000 after acquiring an additional 308,452 shares in the last quarter. Citadel Advisors LLC acquired a new position in shares of Ra Pharmaceuticals in the third quarter worth about $4,664,000. Sectoral Asset Management Inc lifted its stake in shares of Ra Pharmaceuticals by 55.6% in the third quarter. Sectoral Asset Management Inc now owns 278,082 shares of the company’s stock worth $4,060,000 after acquiring an additional 99,332 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Ra Pharmaceuticals by 28.2% in the third quarter. JPMorgan Chase & Co. now owns 256,300 shares of the company’s stock worth $3,742,000 after acquiring an additional 56,400 shares in the last quarter. Finally, State Street Corp lifted its stake in shares of Ra Pharmaceuticals by 40.3% in the second quarter. State Street Corp now owns 151,063 shares of the company’s stock worth $2,830,000 after acquiring an additional 43,376 shares in the last quarter. Institutional investors and hedge funds own 47.86% of the company’s stock.
WARNING: This report was first reported by WKRB News and is owned by of WKRB News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.wkrb13.com/2018/04/01/short-interest-in-ra-pharmaceuticals-inc-rarx-expands-by-52-2.html.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.